Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma

Monoclonal antibodies are at the vanguard of the most promising cancer treatments. Whereas traditional therapeutic antibodies have been limited to extracellular antigens, T cell receptor mimic (TCRm) antibodies can target intracellular antigens presented by cell surface major histocompatibility comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chang, Liu, Hong, Dasgupta, Moumita, Hellman, Lance M., Zhang, Xiaogang, Qu, Kai, Xue, Hui, Wang, Yun, Fan, Fenling, Chang, Qi, Yu, Duo, Ge, Linhu, Zhang, Yu, Cui, Ziyou, Zhang, Pengbo, Heller, Bradley, Zhang, Hongbing, Shi, Bingyin, Baker, Brian M., Liu, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287321/
https://www.ncbi.nlm.nih.gov/pubmed/35840635
http://dx.doi.org/10.1038/s41598-022-15946-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287321/
https://www.ncbi.nlm.nih.gov/pubmed/35840635
http://dx.doi.org/10.1038/s41598-022-15946-5

Ejemplares similares